EDSA - Edesa Biotech Corp Trailing Twelve Months Revenue Growth

On GURU.Markets, the last twelve months (LTM) revenue growth rate for Edesa Biotech, Inc. (EDSA) reflects a trend where the value remains at 0.00. Edesa Biotech, Inc. (EDSA) is actively developing its pipeline of treatments for inflammation and ARDS. The company's revenues are based on hospital procurement and insurance payouts. Success is driven by the recruitment of top dermatologists, who are incentivized by stock options tied to the completion of FDA milestones.
edesabiotech.com (EDSA) - metric breakdowns and financial figures

Year-over-year (TTM) sales growth captures the daily dynamics of annual revenue to assess the operational resilience of the business. This metric allows an investor to detect a slowdown in expansion prior to the publication of official reports. By analyzing the TTM revenue growth trajectory compared to the previous year, one can evaluate the company's reaction to macroeconomic shocks. For Edesa Biotech, Inc. (EDSA), this indicator is critical, as commercial sales are non-existent. Currently, the company operates using existing reserves to fund costly clinical trials.